Tehfe, M., Lee, J., Rha, S. Y., Nakamura, Y., Tabernero, J., Shitara, K., … Strickler, J. H. (2023). 1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC). In Annals of Oncology (Vol. 34, pp. S857–S858). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.09.1436

Tehfe, M., J. Lee, S. Y. Rha, Y. Nakamura, J. Tabernero, K. Shitara, D. -. Y. Oh, et al. “1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC).” In Annals of Oncology, 34:S857–58. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.09.1436.

Tehfe M, Lee J, Rha SY, Nakamura Y, Tabernero J, Shitara K, et al. 1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC). In: Annals of Oncology. Elsevier BV; 2023. p. S857–8.

Tehfe, M., et al. “1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC).” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S857–58. Crossref, doi:10.1016/j.annonc.2023.09.1436.

Tehfe M, Lee J, Rha SY, Nakamura Y, Tabernero J, Shitara K, Oh D-Y, Eads J, Marshall J, Wainberg ZA, Lee K-W, Kang Y-K, Liao C-Y, Oh SY, Yeh K-H, Richards D, Ubowski MM, Zhao K, Bhaumik S, Strickler JH. 1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC). Annals of Oncology. Elsevier BV; 2023. p. S857–S858.